Genscript BiotechGNNSF 66 Interest Coverage is 9.87 as of Dec. 2025, which is 89% below its 10-year median of 91.23. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 377 Biotechnology companies, Genscript Biotech ranks worse than 72.41% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genscript Biotech's
Operating Income
for the
six
months ended in Dec. 2025 was $79.8 Mil. Genscript Biotech's Interest Expense for the
six
months ended in Dec. 2025 was $-8.1 Mil.
Genscript Biotech's interest coverage for the quarter that ended in Dec. 2025 was 9.87.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Genscript Biotech's Interest Coverage or its related term are showing as below:
GNNSF'
s Interest Coverage Range Over the Past 10 Years
Min: 2.83 Med: 91.23 Max: No Debt
Current: 15.18
GNNSF's Interest Coverage is ranked worse than 72.41% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs GNNSF: 15.18
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genscript Biotech Interest Coverage Related Terms
Genscript Biotech Interest Coverage Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
GNNSF vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Genscript Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Interest Coverage of 9.87 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genscript Biotech and its competitors. This is 89% below median its historical median of 91.23. Over the past decade, Genscript Biotech's Interest Coverage has ranged from 2.83 to 10,000.00. According to the industry distribution chart, Genscript Biotech ranks #273 out of 377 companies in the Biotechnology industry, placing it in the top 72.4%.
Is Genscript Biotech's Interest Coverage too high?
Genscript Biotech's current Interest Coverage of 9.87 is 89% below median its 10-year median of 91.23. Over the past 10 years, this metric has ranged from a low of 2.83 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. Genscript Biotech's value of 9.87 is 90.7% below this industry median. Based on the distribution chart, Genscript Biotech ranks #273 out of 377 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #273 out of 377 companies for Interest Coverage. This places Genscript Biotech in the lower half of its industry. The industry median Interest Coverage is 106.07. Genscript Biotech's value of 9.87 is 90.7% below this benchmark. Historically, Genscript Biotech's own Interest Coverage has ranged from 2.83 to 10,000.00 over the past decade. While the company's 10-year median is 91.23 vs. the industry median of 106.07, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Interest Coverage of 9.87 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Interest Coverage is 9.87, which is 89% below median its own 10-year median of 91.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Interest Coverage is 9.87, which is 89% below median its 10-year median of 91.23 and 90.7% below the Biotechnology industry median of 106.07. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Interest Coverage is 9.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Interest Coverage: 9.87 (89% below median its 10-year median of 91.23)
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 90.7% below the Biotechnology median (#273 of 377)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
